These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29337226)

  • 1. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence.
    Jerlhag E
    Neuropharmacology; 2018 Jul; 136(Pt B):343-349. PubMed ID: 29337226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1.
    Jerlhag E
    Brain Res; 2020 Jan; 1727():146562. PubMed ID: 31759971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents.
    Vallöf D; Kalafateli AL; Jerlhag E
    Psychoneuroendocrinology; 2019 May; 103():284-295. PubMed ID: 30771711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents.
    Vallöf D; Vestlund J; Jerlhag E
    Neuropharmacology; 2019 May; 149():124-132. PubMed ID: 30772374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.
    Vallöf D; Maccioni P; Colombo G; Mandrapa M; Jörnulf JW; Egecioglu E; Engel JA; Jerlhag E
    Addict Biol; 2016 Mar; 21(2):422-37. PubMed ID: 26303264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.
    Suchankova P; Yan J; Schwandt ML; Stangl BL; Caparelli EC; Momenan R; Jerlhag E; Engel JA; Hodgkinson CA; Egli M; Lopez MF; Becker HC; Goldman D; Heilig M; Ramchandani VA; Leggio L
    Transl Psychiatry; 2015 Jun; 5(6):e583. PubMed ID: 26080318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.
    Klausen MK; Thomsen M; Wortwein G; Fink-Jensen A
    Br J Pharmacol; 2022 Feb; 179(4):625-641. PubMed ID: 34532853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy.
    Engel JA; Jerlhag E
    CNS Drugs; 2014 Oct; 28(10):875-86. PubMed ID: 24958205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide-1 Receptor Signaling in the Ventral Tegmental Area Reduces Alcohol Self-Administration in Male Rats.
    Dixon TN; McNally GP; Ong ZY
    Alcohol Clin Exp Res; 2020 Oct; 44(10):2118-2129. PubMed ID: 33043520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies.
    Jerlhag E
    Front Pharmacol; 2023; 14():1063033. PubMed ID: 37063267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.
    Thomsen M; Holst JJ; Molander A; Linnet K; Ptito M; Fink-Jensen A
    Psychopharmacology (Berl); 2019 Feb; 236(2):603-611. PubMed ID: 30382353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors.
    Sirohi S; Schurdak JD; Seeley RJ; Benoit SC; Davis JF
    Physiol Behav; 2016 Jul; 161():140-144. PubMed ID: 27072507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food.
    Colvin KJ; Killen HS; Kanter MJ; Halperin MC; Engel L; Currie PJ
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents.
    Egecioglu E; Steensland P; Fredriksson I; Feltmann K; Engel JA; Jerlhag E
    Psychoneuroendocrinology; 2013 Aug; 38(8):1259-70. PubMed ID: 23219472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse.
    Jerlhag E
    Pharmacol Ther; 2019 Apr; 196():1-14. PubMed ID: 30439457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs.
    Bornebusch AB; Fink-Jensen A; Wörtwein G; Seeley RJ; Thomsen M
    eNeuro; 2019; 6(2):. PubMed ID: 31058214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice.
    Thomsen M; Dencker D; Wörtwein G; Weikop P; Egecioglu E; Jerlhag E; Fink-Jensen A; Molander A
    Pharmacol Biochem Behav; 2017 Sep; 160():14-20. PubMed ID: 28778739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine.
    Schmidt HD; Mietlicki-Baase EG; Ige KY; Maurer JJ; Reiner DJ; Zimmer DJ; Van Nest DS; Guercio LA; Wimmer ME; Olivos DR; De Jonghe BC; Hayes MR
    Neuropsychopharmacology; 2016 Jun; 41(7):1917-28. PubMed ID: 26675243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study.
    Farokhnia M; Browning BD; Crozier ME; Sun H; Akhlaghi F; Leggio L
    Addict Biol; 2022 Sep; 27(5):e13211. PubMed ID: 36001436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice.
    Allingbjerg ML; Hansen SN; Secher A; Thomsen M
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):612-620. PubMed ID: 36480394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.